HCPLive

Kynamro Approved for Genetic Condition Tied to Cholesterol

 
WEDNESDAY, Jan. 30 (HealthDay News) -- Kynamro (mipomersen sodium) has been approved by the U.S. Food and Drug Administration to treat homozygous familial hypercholesterolemia (HoFH), a rare inherited condition in which the body can't remove low-density lipoprotein (LDL) cholesterol from the blood, as an addition to lipid-lowering medications and diet.

Many people with HoFH have a heart attack and die before age 30, the FDA said in a news release. HoFH affects approximately one in every one million people in the United States. Kynamro is a once-weekly injection designed to lower creation of blood lipid particles that ultimately form LDL, the agency said.

The drug was clinically evaluated among 51 people with HoFH. Among Kynamro users, LDL levels fell an average of about 25 percent during the first 26 weeks, the FDA said. The drug will carry a "black box" label warning of possible liver abnormalities that could lead to progressive liver disease.

More common side effects noted during clinical testing included injection-site reactions, flu-like symptoms, nausea, headache, and elevated liver enzymes.

Kynamro is produced by Genzyme Corp., of Cambridge, Mass.
 

More Information


Copyright © 2013 HealthDay. All rights reserved.
 
 

Most Popular

Recommended Reading

As good news about new treatments for hepatitis C infections continues to dominate the International Liver Congress, Texas researchers today reported more success with sofosbuvir and daclatasvir.
Video Interview: Vinood Patel, PhD, PGCHE, fHEA, FRSC, University of Westminster, London, UK, shared valuable insight regarding chronic alcoholic demographics and biomarkers on the horizon at The International Liver Congress 2015.
The use of interferon to treat hepatitis C infections has fallen out of favor with the advent of new antivirals and drug combinations that have fewer side effects. But in a study presented at the 2015 International Liver Congress in Vienna, Austria, researchers from the UK said that physicians should put interferon back on the treatment menu.
In this video interview, Camille Barrault, MD, spoke about the implications her work with baclofen could have for the future of liver disease research at The International Liver Congress 2015, Vienna, Austria.
$vAR$